Abstract
Cardiopulmonary arrest is one of the leading causes of death and disability, primarily occurring in the aged population. Numerous global cerebral ischemia animal models induce neuronal damage similar to cardiac arrest. These global cerebral ischemia models range from vessel occlusion to total cessation of cardiac function, both of which have allowed for the investigation of this multifaceted disease and detection of numerous agents that are neuroprotective. Synapses endure a variety of alterations after global cerebral ischemia from the resulting excitotoxicity and have been a major target for neuroprotection; however, neuroprotective agents have proven unsuccessful in clinical trials, as neurological outcomes have not displayed significant improvements in patients. A majority of these neuroprotective agents have specific neuronal targets, where the success of future neuroprotective agents may depend on non-specific targets and numerous cognitive improvements. This review focuses on the different models of global cerebral ischemia, neuronal synaptic alterations, synaptic neuroprotection and behavioral tests that can be used to determine deficits in cognitive function after global cerebral ischemia.
Keywords: Aging, cardiac arrest, global cerebral ischemia, hippocampus, neuroprotection, synapse
Current Drug Targets
Title:Global Cerebral Ischemia: Synaptic and Cognitive Dysfunction
Volume: 14 Issue: 1
Author(s): Jake T. Neumann, Charles H. Cohan, Kunjan R. Dave, Clinton B. Wright and Miguel A. Perez-Pinzon
Affiliation:
Keywords: Aging, cardiac arrest, global cerebral ischemia, hippocampus, neuroprotection, synapse
Abstract: Cardiopulmonary arrest is one of the leading causes of death and disability, primarily occurring in the aged population. Numerous global cerebral ischemia animal models induce neuronal damage similar to cardiac arrest. These global cerebral ischemia models range from vessel occlusion to total cessation of cardiac function, both of which have allowed for the investigation of this multifaceted disease and detection of numerous agents that are neuroprotective. Synapses endure a variety of alterations after global cerebral ischemia from the resulting excitotoxicity and have been a major target for neuroprotection; however, neuroprotective agents have proven unsuccessful in clinical trials, as neurological outcomes have not displayed significant improvements in patients. A majority of these neuroprotective agents have specific neuronal targets, where the success of future neuroprotective agents may depend on non-specific targets and numerous cognitive improvements. This review focuses on the different models of global cerebral ischemia, neuronal synaptic alterations, synaptic neuroprotection and behavioral tests that can be used to determine deficits in cognitive function after global cerebral ischemia.
Export Options
About this article
Cite this article as:
T. Neumann Jake, H. Cohan Charles, R. Dave Kunjan, B. Wright Clinton and A. Perez-Pinzon Miguel, Global Cerebral Ischemia: Synaptic and Cognitive Dysfunction, Current Drug Targets 2013; 14 (1) . https://dx.doi.org/10.2174/1389450111314010004
DOI https://dx.doi.org/10.2174/1389450111314010004 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Peripartum Cardiomyopathy: Moving Towards a More Central Role of Genetics
Current Cardiology Reviews Adeno-associated Viral Vectors for Correction of Inborn Errors of Metabolism: Progressing Towards Clinical Application
Current Pharmaceutical Design Cardiovascular Risk Factors, Metabolic Complications, & the Natural Course of CKD in Children
Current Hypertension Reviews A Review of Patents on Implantable Heart-Compression/Assist Devices and Systems
Recent Patents on Biomedical Engineering (Discontinued) Mitochondrial Complex I Deficiency in Humans
Current Genomics Modulation of Collagen Turnover in Cardiovascular Disease
Current Pharmaceutical Design T Lymphocytes as Targets of Statins: Molecular Mechanisms and Therapeutic Perspectives
Inflammation & Allergy - Drug Targets (Discontinued) Hydrogen Sulfide in Diabetic Complications: Focus on Molecular Mechanisms
Endocrine, Metabolic & Immune Disorders - Drug Targets Treatment of the Cheyne-Stokes Breathing Pattern in Patients with Congestive Heart Failure: State of the Art
Current Respiratory Medicine Reviews Anti-Hyperglycemic and Hypolipidemic Effects of Different Aloe vera (Aloe Barbadensis Miller) Extracts in the Management of Obesity and Diabetes
Current Nutrition & Food Science Epidermolysis Bullosa: Pediatric Perspectives
Current Pediatric Reviews Pleiotropic Effects of Fenofibrate
Current Pharmaceutical Design Atrial Conduction Disorders
Current Cardiology Reviews Comparison of High-Sensitive CRP, RDW, PLR and NLR between Patients with Chronic Obstructive Pulmonary Disease and Chronic Heart Failure
Current Respiratory Medicine Reviews Expression and Function of MicroRNAs in Heart Disease
Current Drug Targets Hsp70 Protein Complexes as Drug Targets
Current Pharmaceutical Design Editorial [Hot Topic:Applications of Angiotensin Converting Enzyme Inhibitors and of Angiotensin II Receptor Blockers in Pharmacology and Therapy: An Update (Executive Editor: Agostino Molteni)]
Current Pharmaceutical Design The Involvement of Lysosomes in Myocardial Aging and Disease
Current Cardiology Reviews Vascular Pathology from Smoking: Look at the Microcirculation!
Current Vascular Pharmacology Dysregulation of Neurotrophic and Haematopoietic Growth Factors in Alzheimer’s Disease: From Pathophysiology to Novel Treatment Strategies
Current Alzheimer Research